Soliris to Ultomiris...generation shift picks up speed
By Kim, Jin-Gu | translator Alice Kang
22.05.25 12:08:50
가나다라
0
Quarterly sales of PNH treatment Soliris drop sharply from ₩11.4 billion to ₩2.8 billion in one year
Follow-on drug Ultomiris raises ₩9.6 billion in sales in Q1…replaces Soliris
Whether Handok’s strategy of keeping Soliris’ biosimilars in check before their release will work receive attention
The generation shift between Handok’s paroxysmal nocturnal hemoglobinuria treatments Soliris (eculizumab) and Ultomiris (ravulizumab) is gaining speed.
With Ultomiris quickly replacing Soliris, Handok’s strategy of checking the release of Soliris’s biosimilars is also being considered a success.
◆Sales of Soliris drop 75%… replaced by its follow-on Ultomiris
According to the market research institution IQVIA on the 24th, Soliris’s sales in Q1 this year recorded ₩2.8 billion. This is a 76% drop from the ₩11.4 billion it had made in Q1 2021.
However, the rise in Ultromiris’s sales more than made up for the reduced sales of Soliris. Ultrom
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)